Login to Your Account

Decelerated Approvals?

FDA Slows Pedal-to-Metal AML Bids, Nixes Single-Arm Strategy

By Randy Osborne

Monday, December 21, 2009
Bad news last week from the FDA for cash-strapped Vion Pharmaceuticals Inc. regarding Onrigin pointed up the need for a better therapy against acute myeloid leukemia in the elderly as well as the difficulty in developing one that works and can pass muster with regulators.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription